期刊
CURRENT PHARMACEUTICAL DESIGN
卷 21, 期 28, 页码 4000-4006出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612821666150826095346
关键词
Abdominal aortic aneurysm; statins; renin angiotensin system; tetracyclines; interleukin-1 beta
资金
- Novartis Consumer Health Foundation
- Swiss National Science Foundation [310030_156859/1]
- Special Research Fund of Ghent University
- Laboratory of Hemodynamics and Cardiovascular Technology - EPFL
- Flemish Fund for Scientific Research
- Swiss National Science Foundation (SNF) [310030_156859] Funding Source: Swiss National Science Foundation (SNF)
Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established drug therapy for AAA. Since the probability of death from a ruptured AAA still remains high, preventive elective repair of AAAs larger than 5.5 cm in luminal diameter is considered the best treatment option. However, perioperative complications are problematic as elective AAA repair comes with numerous intrinsic risks. Impelled by the need of improving AAA therapy, significant efforts have been made to identify pharmacological tools that would slow down AAA enlargement and lower the risk of rupture, thereby reducing the necessity of surgical intervention. In this review, we discuss recent findings addressing molecular targets that could potentially treat AAA, particularly addressing: statins, classical renin angiotensin system (RAS) blockers, the protective arm of RAS, renin inhibitors, tetracyclines, interleukin-1 beta inhibition, anti-angiogenic agents and urocortins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据